Healthcare & Life Sciences
Retro Biosciences
Retro Biosciences is a longevity biotech startup backed by OpenAI CEO Sam Altman (a $180 million seed investment) developing therapies aimed at extending human healthspan, including a clinical-stage pill designed to enhance the body's ability to clear protein aggregates in Alzheimer's disease patients. The company reached a $1.8 billion valuation as of May 2026 after raising additional capital beyond its initial $1 billion Series A target of a $5 billion valuation, following a Q1 2025 $1 billion round that was, at the time, the largest single longevity-biotech funding deal on record.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source · 46% avg. source confidence
- STAT News — Retro Biosciences reaches $1.8B valuation46% source confidence
Dependency Map
What Retro Biosciences depends on below, and who depends on Retro Biosciences above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Retro Biosciences's Timeline
A sourced, dated history of Retro Biosciences's key moments — founding to present.
Jan 2021 · Founded with $180M Sam Altman seed investment
Retro Biosciences was founded with a $180 million seed investment from OpenAI CEO Sam Altman to develop therapies extending human healthspan.
2025-Q1 · Raises $1B, largest longevity-biotech deal on record
Retro Biosciences raised $1 billion in the largest single longevity-biotech funding deal on record at the time, initially targeting a $5 billion valuation.
May 2026 · Reaches $1.8B valuation, advances Alzheimer's clinical trial
Retro Biosciences reached a $1.8 billion valuation as of May 2026 while running its first clinical trial, testing a pill designed to enhance the body's ability to clear protein aggregates in Alzheimer's disease patients.